A St. Louis jury handed Abbott Laboratories a win Thursday, deciding that Abbott, another company and a hospital were not ...

Abbott Laboratories showcases robust financial performance with a notable increase in net earnings. Strategic acquisitions and product launches strengthen the company's market presence.

Marie Thibault, an analyst from BTIG, reiterated the Buy rating on Abbott Laboratories (ABT – Research Report). The associated price ...

In the last three months, 15 analysts have published ratings on Abbott Laboratories (NYSE:ABT), offering a diverse range of perspectives from bullish to bearish. The table below summarizes their ...

So on that note, Abbott Laboratories (NYSE:ABT) looks quite promising in regards to its trends of return on capital. What Is Return On Capital Employed (ROCE)? Just to clarify if you're unsure ...

Oppenheimer analyst Suraj Kalia maintained a Buy rating on Abbott Laboratories (ABT – Research Report) today and set a price target of ...

CNBC's Jim Cramer on Friday evaluated the stock of Abbott Laboratories, a healthcare company that's been weighed down by ongoing litigation for several months. Abbott was cleared Thursday night of ...

On Monday, Barclays maintained an Overweight rating on Abbott Labs (NYSE:ABT) shares and increased the price target to $149 from $143. The adjustment follows a favorable verdict for Abbott in a ...

Abbott Laboratories and Reckitt Benckiser shares surged on Friday after a Missouri court ruled in the two companies’ favor in a dispute over claims their specialist infant formulas had caused a ...